• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,802.90 -607.08
( -0.78%)
Global Indices
Nasdaq
51,585.70 72.15
(0.14%)
Dow Jones
7,521.58 80.48
(1.08%)
Hang Seng
70,971.12 -82.37
(-0.12%)
Nikkei 225
10,357.71 -41.99
(-0.40%)
Forex
USD-INR
94.39 -0.12
(-0.13%)
EUR-INR
108.40 -1.03
(-0.94%)
GBP-INR
125.08 -1.43
(-1.13%)
JPY-INR
0.59 0.00
(-0.50%)

EQUITY - MARKET SCREENER

Divis Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
532488
INE361B01024
629.4942217
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DIVISLAB
67.22
178956.35
EPS(TTM)
Face Value()
Div & Yield %
100.29
2
0.44
 

nuvama wealth management ltd
Vivanza Biosciences reports consolidated net loss of Rs 0.45 crore in the March 2026 quarter
May 08,2026
Net Loss of Vivanza Biosciences reported to Rs 0.45 crore in the quarter ended March 2026 as against net loss of Rs 1.00 crore during the previous quarter ended March 2025. Sales rose 1225.00% to Rs 6.36 crore in the quarter ended March 2026 as against Rs 0.48 crore during the previous quarter ended March 2025.

For the full year,net profit reported to Rs 0.39 crore in the year ended March 2026 as against net loss of Rs 0.67 crore during the previous year ended March 2025. Sales rose 1462.13% to Rs 115.91 crore in the year ended March 2026 as against Rs 7.42 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales6.360.48 1225 115.917.42 1462
OPM %-3.62-200.00 -0.63-4.85 -
PBDT-0.29-0.99 71 0.57-0.65 LP
PBT-0.30-0.99 70 0.54-0.67 LP
NP-0.45-1.00 55 0.39-0.67 LP